This Genentech and Biogen Idec promotional ancillary event, in partnership with ONSEdge, Inc., a subsidiary of the Oncology Nursing Society (ONS), is being held in conjunction with the ONS 10th Annual Institutes of Learning and Advanced Practice Nursing Conferences.

About the Program

The immune system protects the body from a whole range of diseases, including bacterial infections, viruses, fungi, parasites, and tumor cells, by detecting infections, eliminating and eradicating them, and then protecting the body from recurrences. The primary cell type of the immune system-the B-cell-is responsible for preventing reinfection and producing antibodies. This program describes the role that Rituxan plays in treating certain patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL), a type of cancer that develops with the B-cell mutates and becomes cancerous.

Target Audience

This program has been designed especially for oncology nurses and nurse practitioners involved in the treatment of patients with non-Hodgkin’s lymphoma (NHL).

Faculty

Sheila Arrington, RN, MSN, GNP-BC
Nurse Practitioner
Wake Forest University Baptist Medical Center
Winston Salem, North Carolina

Learning Objectives

At the end of this presentation, the participant will be able to:

• Review past and current trends in lymphoma diagnosis and staging
• Elevated advanced practitioners’ understanding of non-Hodgkin’s lymphoma to more effectively partner with physicians in treatment decision making
• Provide advanced practitioners with tools to facilitate communication of diagnoses and prognoses to patients

Program Outline

ONSEdge, Inc., has been assigned meeting space to provide an ancillary event during the ONS 10th Annual Institutes of Learning and Advanced Practice Nursing Conference, November 12-15, 2009, in Tampa, FL. The ONS assignment of meeting space does not imply product endorsement, nor does the ONS assume any responsibility for the content.

RSVP deadline 11/12/09—5 PM EST

Note: NO continuing nursing education (CNE) contact hours will be awarded.

Indications
RITUXAN^® (Rituximab) is indicated for the treatment of patients with:
• Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
• Weekly ×4 • Weekly ×8 • Bulky disease • Retreatment
• Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
• Non-progressing (including stable disease), low-grade, CD20-positive B-cell NHL, as a single agent, after first-line CVP chemotherapy
• Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
BOXED WARNINGS and Additional Important Safety Information
The most important serious adverse reactions of RITUXAN are fatal infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation with fulminant hepatitis, other viral infections, cardiovascular events, renal toxicity, and bowel obstruction and perforation. The most common adverse reactions of RITUXAN (incidence ≥25%) observed in patients with NHL are infusion reactions, fever, chills, infection, asthenia, and lymphopenia.
For additional safety information, please see the brief summary of prescribing information on reverse page.
Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.

©2009 Genentech USA, Inc All rights reserved. 9951500 September 2009